Table 3.

Thromboembolic events pre- and post-hematopoietic stem cell transplant in patients with pMDS/BMF due to germline GATA2 mutations compared to control A (pMDS/BMF without GATA2 mutations) and control B (ALL/AML without GATA2 mutations)

		n (%) GATA2 cohort n=15	n (%) Control A n=25	n (%) Control B n=40	p-value for GATA2 vs Control A*	p-value for GATA2 vs Control B*
Total number of patients with thrombosis n (%)		8 (53)	0 (0)	4 (10)	<0.0001	0.0015
Number of patients with thromboembolic events in relation to HSCT, n (%)	Pre-HSCT	2 (13)	0 (0)	4 (10)	0.13	0.5
	Post-HSCT	6 (40)	0 (0)	0 (0)	0.0013	0.0002
Number of patients with thromboembolic events post-HSCT, by type**, n (%)	DVT	4 (27)	0 (0)	0 (0)	0.015	0.004
	PE	2 (13)	0 (0)	0 (0)	0.13	0.071
	Stroke	1 (7)	0 (0)	0 (0)	0.38	0.27
Number of patients with Post-HSCT thrombosis CVL associated, n (%)	Yes, n (%)	1/6 (17)	NA	NA	NA	NA

^*p-values are one-sided, testing for higher proportion of events in GATA2 group compared with control groups. HSCT – hematopoietic stem cell transplant; NA – Not applicable; CVL – central venous line

^**one patient had two types of thromboembolic events post-SCT: one DVT and one PE.